Pharmacyclics reports total GAAP revenues of $2.1 million for third-quarter fiscal 2010

Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its third quarter ended March 31, 2010.

Total revenues recognized under GAAP in our most recent quarter was $2.1 million. Upon the signing of a drug supply agreement with Les Laboratories ("Servier") in the quarter ended December 31, 2009, the company began recognizing revenue from its collaboration agreement with Servier, which was entered into in April 2009.

The GAAP net loss for the third quarter of fiscal 2010 was $3.1 million, or $0.06 per share, compared to a net loss of $6.7 million, or $0.25 per share, in the third quarter of fiscal 2009.  

Total operating expenses were $5.3 million in the third quarter of fiscal 2010, including $0.5 million of share-based compensation expense. In the third quarter of 2009, total operating expenses were $6.4 million, including share-based compensation expense of $0.5 million. Excluding share-based compensation expense and a third quarter fiscal 2009 non-recurring expense of $1 million to Celera Corporation ("Celera"), total expenses were $4.8 million for the third quarter of fiscal 2010 compared to $4.9 million in the third quarter of fiscal 2009, a decrease of $0.1 million.

As of March 31, 2010, the company's cash, cash equivalents and marketable securities totaled $27.4 million compared to $16.3 million as of June 30, 2009.  In April 2010, the company received final payment of $0.4 million from its collaboration partner Servier for the shipment of 10kg of its HDAC Inhibitor PCI-24781 and in May received from Servier the semi-annual research payment of $1 million. The company is expecting two additional research collaboration payments of $1 million each over the next twelve months from Servier. In addition the company has filed documents with the US Tax Authority for the repayment of French taxes in the amount of $0.55 million, which the company is expecting to receive before calendar year end 2010.

Most recently, Pharmacyclics participated in an oral presentation for its Btk program at the annual meeting of the American Association of Cancer Research (AACR) on April 20 in Washington, DC, describing the efficacy of the company's first-in-human, selective Btk inhibitor PCI-32765 in a mouse model of pancreatic cancer (Soucek et al). This oral presentation can be viewed on our website at: http://www.pharmacyclics.com/wt/page/btk_inhibitors_publications. Largely based on the work of Dr. Gerard Evan and others at UCSF, mast cells have emerged as an important component of the pro-inflammatory microenvironment, which is crucial for the physical expansion and maintenance of tumor growth (Nature Medicine 13 (10), p. 1211-18).  Dr. Evan's lab tested the company's Btk Inhibitor PCI-32765 in his mouse pancreatic model (InsMycER + RIP-BclxL). In the model, PCI-32765 completely blocked mast cell degranulation, which led to tumor regression and vascular collapse.  These results support the newly developing concept that mast cell inhibition could be beneficial for the treatment of mast cell dependent cancers, and PCI-32765 could open the way to clinical trials assessing this potential.  Dr. Evan is now conducting follow-up experiments with PCI-32765 in other mouse models of mast cell-driven cancer. The mast cell inhibitory properties of Btk inhibitors may as well have applications outside of cancer, for example the treatment of allergies. Additionally at AACR, Pharmacyclics also participated in presenting four abstracts utilizing the company's HDAC molecule. For further information regarding the HDAC posters please go to our website at: http://www.pharmacyclics.com/wt/page/hdac_science.

The company's CEO and Chairman of the Board, Robert W. Duggan, stated, "we are enrolling our Btk oncology program according to plan. Our Btk autoimmune program has also progressed during this past quarter. We identified our clinical development candidate Btk Inhibitor PCI-45292 and plan to file an investigational new drug application in the first half of 2011. The Btk Inhibitor for autoimmune diseases, PCI-45292, is based on the chemical scaffold developed for the Btk Inhibitor PCI-32765, and is optimized for chronic dosing in non-oncology applications."

Mr. Duggan concluded: "As many of our shareholders know, we submitted our Btk inhibitor trial results in an abstract to be presented at the upcoming American Society for Clinical Oncology (ASCO) meeting on June 4-8, 2010. We are pleased to announce that our abstract was selected to be among the few to be presented in an Oral Session. Less than 5% of all abstracts submitted were selected for an oral presentation. The oral presentation will be on Saturday June 5th between 1:00 pm and 4:00 pm at ASCO in E354a. The Permanent Abstract ID is 8012. The abstract title is 'Btk inhibitor PCI-32765 monotherapy induces objective responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study'. ASCO's regulations require us not to disclose any information contained in this oral presentation prior to the meeting.  In an effort to avoid a conflict we will hold a conference call after we release the pending Btk inhibitor clinical trial results at ASCO. A conference call is scheduled for Monday, June 7, 2010 at 8:30am EDT, we will provide you with dial-in numbers as we approach this event. We are anticipating to have clinical data on over 20 additional patients at that time and plan to provide a full update on the status of all the cohorts of our Phase I trial. In addition, we will provide a full update on each of our novel drug programs and respond to any questions presented regarding our business."